Answer
Developing antibodies to infliximab is associated with more frequent infusion reactions, a small proportion of which are serious allergic reactions, and a reduced duration of response.
Sources for this answer
- Remicade 100mg powder for concentrate for solution for infusionJanssen-Cilag Ltd (a Johnson & Johnson Company) · emc · SmPC §4.4 Special warnings and precautions for use · Version 75Document updated
Sources checked